KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Convertible Debt (2018 - 2025)

Exact Sciences (EXAS) has disclosed Convertible Debt for 8 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • Quarterly Convertible Debt changed 0.26% to $2.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, changed 0.26% year-over-year, with the annual reading at $2.3 billion for FY2025, 0.26% changed from the prior year.
  • Convertible Debt for Q4 2025 was $2.3 billion at Exact Sciences, roughly flat from $2.3 billion in the prior quarter.
  • The five-year high for Convertible Debt was $2.3 billion in Q4 2025, with the low at $1.9 billion in Q1 2021.
  • Average Convertible Debt over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2023.
  • The sharpest move saw Convertible Debt grew 23.03% in 2021, then dropped 10.54% in 2024.
  • Over 5 years, Convertible Debt stood at $2.2 billion in 2021, then grew by 0.27% to $2.2 billion in 2022, then grew by 5.86% to $2.3 billion in 2023, then increased by 0.29% to $2.3 billion in 2024, then increased by 0.26% to $2.3 billion in 2025.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $2.3 billion, $2.3 billion, and $2.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.